<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03460041</url>
  </required_header>
  <id_info>
    <org_study_id>N-59-2017</org_study_id>
    <nct_id>NCT03460041</nct_id>
  </id_info>
  <brief_title>Caudal Dexmetedomedine Versus Magnesium in Orthopedic Pediatric Surgeries</brief_title>
  <official_title>Caudal Dexmetedomedine Versus Magnesium in Orthopedic Pediatric Surgeries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hagar hassanein refaee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be performed in Abo Elreesh Pediatric Hospital / Cairo University after
      obtaining approval by the University Ethics Committee, and a written informed consent from
      the parents or guardians.

      Thirty six patients will be randomly assigned using an online randomization program
      (http://www.randomizer.org) and the sealed envelope method into three groups: Group D (n=12):
      Dexmetedomidine group. 0.5 ml of dexmetedomidine (2 Î¼g/kg) added to bupivacaine, Group M
      (n=12) : Magnesium group.0.5 ml of magnesium sulphate (50 mg) added to bupivacaine, Group C
      (n=12) :Control group.bupivacaine 0.25% diluted in normal saline with total volume of 1
      ml/kg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      History regarding previous anesthesia, surgery, any significant medical illness, medications
      and allergy will be taken for all children who will be enrolled in the study. Complete
      physical examination and airway assessment will be done. Hemoglobin percentage, blood sugar
      and coagulation profile will be investigated preoperatively Sedation will be done by giving
      midazolam (0.2 mg/kg IM).On arrival to the operating room all patients will be monitored by 5
      leads electrocardiography (ECG), automated non-invasive blood pressure monitoring (NIBP), and
      pulse oximetery.

      Inhalational induction of anesthesia will be achieved by 8% sevoflurane in 100% oxygen and an
      appropriate-sized cannula will be inserted. Endotracheal intubation will be performed after
      which sevoflurane concentration will be reduced to 3%. After hemodynamic stabilization,
      caudal block will be performed by using beveled needle 18-23 G in the lateral decubitus
      position by using the loss of resistance technique. The study solutions will be injected
      caudally slowly with repetitive intermittent aspiration by an anesthesiologist blinded to the
      test drugs. The inhaled concentration of sevoflurane will be adjusted to achieve hemodynamic
      changes less than 30% of the preoperative values

      Recorded Parameters for the study:

      Intraoperative hemodynamic: heart rates (beats/minutes), mean arterial blood pressure (mmHg)
      after stabilization, before skin incision and every 15 minutes till the end of surgery.

      Sedation score: Sedation will be monitored after PACU arrival using Ramsay score with its 0-6
      score range.

      Pain score (FLACC score) with its 0-10 score range, each patient pain intensity will be
      assessed at the end of surgery and 12 hours postoperatively.

      Time of rescue analgesia (from the time of caudal injection to the time at which FLACC score
      4 or more) will be recorded.

      Complication secondary to test drugs in the form of toxicity like postoperative nausea and
      vomiting, respiratory depression, hematoma, bradycardia (HR &lt;80 BPM) and hypotension (SBP &lt;70
      mmhg+ age in years * 2) and complication secondary to caudal block; infection, hematoma and
      pain at the site of injection will be recorded.

      Total doses of rescue drugs will be calculated for each group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">March 15, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>12 hours</time_frame>
    <description>Comparing duration of analgesia between caudal magnesium and caudal dexmetedomedine using flacc score</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Pain in Pediatric Patients</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnesium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmetedomedine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Sulfate</intervention_name>
    <description>caudal magnesium sulphate added to bupivacaine for pain management</description>
    <arm_group_label>Magnesium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmetedomedine</intervention_name>
    <description>Caudal dexmetedomedine added to bupivacaine for pain management</description>
    <arm_group_label>Dexmetedomedine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Caudal bupivacaine for pain management</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 1 - 7 years old.

          -  American Society of Anesthesiologist (ASA) physical status class I- II.

          -  Patients scheduled for infra-umbilical orthopedic surgeries.

        Exclusion Criteria:

          -  Patients with known allergy to the study drugs

          -  Suspected coagulopathy.

          -  Infection at the site of caudal block.

          -  History of developmental delay or neuromuscular disorders.

          -  Skeletal deformities.

          -  Patients on magnesium therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hagar Hassanein Refaee, Assistant lecturer</last_name>
    <phone>01063949855</phone>
    <email>bibo_gogo12@yahoo.Com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mai Ahmed Aly, Lecturer</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cairo University faculty</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cairo University</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2018</study_first_submitted>
  <study_first_submitted_qc>March 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2018</study_first_posted>
  <last_update_submitted>March 4, 2018</last_update_submitted>
  <last_update_submitted_qc>March 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Hagar hassanein refaee</investigator_full_name>
    <investigator_title>Assistant lecturer</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

